Press Release: Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021
Press Release: Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021
Press Release: Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021
新闻稿：Xencor将于2021年2月23日主持2020年第四季度和全年财务业绩网络广播和电话会议
Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021
Xencor将于2021年2月23日主持2020年第四季度和全年财务业绩网络广播和电话会议
MONROVIA, Calif.--(BUSINESS WIRE)--February 16, 2021--
加利福尼亚州蒙罗维亚--(美国商业新闻网)--2021年2月16日--
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release fourth quarter and full year 2020 financial results after the market closes on Tuesday, February 23, 2021.
亚洲网加利福尼亚州圣何塞2月23日电Xencor公司(纳斯达克市场代码：XNCR)是一家临床阶段的生物制药公司，开发用于治疗癌症和自身免疫性疾病的工程单克隆抗体和细胞因子。该公司今天宣布，将在2021年2月23日(星期二)市场收盘后公布2020年第四季度和全年的财务业绩。
Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.
Xencor管理层将在当天下午4：30主持网络广播和电话会议。美国东部时间(下午1：30)PT)讨论财务结果并提供公司最新情况。
The live call may be accessed by dialing (877) 359-9508 for domestic callers or +1 (224) 357-2393 for international callers and referencing conference ID number 1163598. A live webcast of the conference call will be available online from the Investors section of the Company's website at www.xencor.com. The webcast will be archived on the company's website for 30 days.
可以通过拨打(877)359-9508(国内主叫方)或+1(224)357-2393(国际主叫方)并参考会议ID号码1163598来接听现场通话。电话会议的网络直播可从公司网站www.xencor.com的投资者栏目在线收看。网络直播将在公司网站上存档30天。
About Xencor, Inc.
关于Xencor公司
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb(R) technology are in clinical development internally and with partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
Xencor是一家临床阶段的生物制药公司，开发用于治疗癌症和自身免疫性疾病的工程化单克隆抗体和细胞因子。目前，由Xencor公司的XmAb(R)技术设计的20个候选药物正在内部和与合作伙伴进行临床开发。Xencor的XmAb工程技术可以对蛋白质的结构进行微小的改变，从而产生新的治疗作用机制。欲了解更多信息，请访问www.xencor.com。
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216006095/en/
在business wire.com上查看源代码版本：https://www.businesswire.com/news/home/20210216006095/en/
CONTACT: Charles Liles
联系人：查尔斯·莱尔斯(Charles Liles)
cliles@xencor.com
邮箱：cliles@xencor.com
Media Contact
媒体联系人
Jason I. Spark
杰森·I·斯帕克
Canale Communications
运河通信
619-849-6005
619-849-6005
jason@canalecomm.com
邮箱：jason@canalecomm.com
(END) Dow Jones Newswires
(完)道琼通讯社
February 16, 2021 16:05 ET (21:05 GMT)
2021年2月16日东部时间16：05(格林尼治标准时间21：05)
译文内容由第三方软件翻译。